Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Inorg Chem ; 63(7): 3335-3347, 2024 Feb 19.
Artículo en Inglés | MEDLINE | ID: mdl-38323844

RESUMEN

A new type of aggregation-induced emission (AIE) luminogen containing a dimeric metal fragment and two or three phthalazine ligands is described, which shows dynamic motions of ligands around the metal centers in solution. Based on the variable-temperature and EXSY NMR spectroscopy data, X-ray crystallography structures, and computational results, three different pathways (i.e., reversible exchange with haptotropic shifts, circulation of ligands around the dimeric metal fragment, and walking on the spot of ligands on the metal centers) were considered for this dynamic behavior. Restriction of these dynamic processes in the aggregate forms of the compounds (in H2O/CH3CN solvent mixtures) contributes to their AIE. DFT calculations and NMR analysis showed that bright excited states for these molecules are not localized on isolated molecules, and the emission of them stemmed from π-dimers or π-oligomers. The morphologies and the mode of associations in the solvent mixtures were determined by using transmission electron microscopy (TEM) and concentration-dependent NMR spectroscopy. The computational results showed the presence of a conical intersection (CI) between the S0 and S1 excited state, which provides an accessible pathway for nonradiative decay in these systems.

2.
J Biochem Mol Toxicol ; 34(10): e22557, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32583933

RESUMEN

Today, it has been proven that the nanoparticles such as superparamagnetic iron oxide nanoparticles (SPIONs) have widespread use in biomedical applications, for instance, in magnetic resonance imaging and targeted delivery of drugs. Despite many studies on SPIONs in diagnosing some diseases like cancer, it has not been investigated on the oral tongue squamous cell carcinoma (OTSCC) detection by the NPs. Hence, the present study has been designed to assess the in vitro cytotoxicity of SPIONs on the isolated mitochondria of OTSCC by mitochondrial tests. Isolated mitochondria were removed from the separated cancer and control tissues from the squamous cells of tango in male Wistar rats (6 or 8 weeks) and exposed to the different concentrations of SPIONs (30, 60, and 120 nM). A rise in the production of reactive oxygen species is one of the significant mechanisms of this study, followed by a collapse of mitochondrial membrane potential, the escape of mitochondrial cytochrome c, and mitochondrial swelling in the exposed isolated mitochondria of OTSCC with SPIONs. Furthermore, our results indicated that the exposure to the SPIONs reduced the activity of succinate dehydrogenase in complex II of the mitochondria obtained from cancerous oral tongue squamous. So the SPIONs can induce selective cytotoxicity on the OTSCC mitochondria without significant effects on the control mitochondria. Based on the results and further studies about in vivo experiments in this regard, it is concluded the SPIONs may be a hopeful therapeutic candidate for the treatment of OTSCC.


Asunto(s)
Antineoplásicos/uso terapéutico , Nanopartículas Magnéticas de Óxido de Hierro , Mitocondrias/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de la Lengua/tratamiento farmacológico , Animales , Antineoplásicos/farmacología , Citocromos c/metabolismo , Técnicas In Vitro , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias/metabolismo , Dilatación Mitocondrial/efectos de los fármacos , Ratas , Especies Reactivas de Oxígeno/metabolismo , Carcinoma de Células Escamosas de Cabeza y Cuello/enzimología , Carcinoma de Células Escamosas de Cabeza y Cuello/metabolismo , Succinato Deshidrogenasa/metabolismo , Neoplasias de la Lengua/enzimología , Neoplasias de la Lengua/metabolismo
3.
Lipids Health Dis ; 19(1): 112, 2020 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-32466773

RESUMEN

BACKGROUND: The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). METHODS: According to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2 groups for taking placebo (n = 30) or 250 mg magnesium oxide plus 150 mg zinc sulfate (n = 30) for 12 weeks. RESULTS: Magnesium and zinc significantly decreased fasting plasma glucose (FPG) (ß - 9.44 mg/dL, 95% CI, - 18.30, - 0.57; P = 0.03) and insulin levels (ß - 1.37 µIU/mL, 95% CI, - 2.57, - 0.18; P = 0.02). Moreover, HDL-cholesterol levels significantly enhanced (ß 2.09 mg/dL, 95% CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (ß - 0.85 mg/L, 95% CI, - 1.26, - 0.45; P < 0.001), a significant increase in total nitrite (ß 5.13 µmol/L, 95% CI, 1.85, 8.41; P = 0.003) and total antioxidant capacity (TAC) (ß 43.44 mmol/L, 95% CI, 3.39, 83.50; P = 0.03) when compared with placebo. Furthermore, magnesium and zinc significantly reduced the Beck Depression Inventory index (BDI) (ß - 1.66; 95% CI, - 3.32, - 0.009; P = 0.04) and Beck Anxiety Inventory (BAI) (ß - 1.30; 95% CI, - 2.43, - 0.16; P = 0.02) when compared with the placebo. CONCLUSIONS: In patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. This suggests that magnesium and zinc co-supplementation may be beneficial for patients with T2DM and CHD. Further studies on more patients and lasting longer are needed to determine the safety of magnesium and zinc co-supplementation. TRIAL REGISTRATION: Current Controlled Trials http://www.irct.ir: IRCT20130211012438N31 at 11 May 2019 of registration. This study retrospectively registered.


Asunto(s)
Glucemia , HDL-Colesterol/sangre , Enfermedad Coronaria/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Suplementos Dietéticos , Magnesio/uso terapéutico , Zinc/uso terapéutico , Antioxidantes/análisis , Proteína C-Reactiva/análisis , Enfermedad Coronaria/sangre , Diabetes Mellitus Tipo 2/sangre , Método Doble Ciego , Humanos , Insulina/sangre , Magnesio/farmacología , Nitritos/sangre , Zinc/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA